What do TSECs provide in the menopausal hormone therapy
2018
AbstractTissue-selective estrogen complex (TSEC) is projected as a progestogen-free option for the treatment of estrogen deficiency symptoms in postmenopausal, non-hysterectomized women. TSEC combines the benefits of estrogen with a selective estrogen receptor modulator (SERM), in this case bazedoxifene acetate (BZA), which has an antagonistic effect on the endometrium, thus avoiding the use of progestins. The authorized TSEC combination (conjugated estrogens [CE] 0.45 mg/BZA 20 mg) for the alleviation of vasomotor symptoms has been demonstrated in randomized clinical trials compared with placebo or menopausal hormone therapy (MHT). In addition, TSEC has shown improvements in quality of life and vaginal atrophy. In respect to MHT using progestins, the benefits of TSEC are found mainly in the bleeding pattern, amenorrhea rate, and reduction in mammary repercussion (i.e., breast tenderness and radiological density). The objective of this guide will be to analyze the efficacy and safety of TSEC consisting of...
Keywords:
- Placebo
- Randomized controlled trial
- Selective estrogen receptor modulator
- Endometrium
- Estrogen
- Endocrinology
- Oncology
- Amenorrhea
- Vasomotor
- Internal medicine
- Medicine
- Vaginal atrophy
- Vaginal disease
- Diabetes mellitus
- Selective estrogen receptor modulators
- postmenopausal women
- Bone density
- Menopausal hormone therapy
- Menopause
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
57
References
1
Citations
NaN
KQI